NASDAQ:SNGX Soligenix (SNGX) Stock Price, News & Analysis $2.26 -0.01 (-0.44%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$2.26▼$2.3450-Day Range$2.23▼$6.6452-Week Range$2.00▼$32.00Volume23,686 shsAverage Volume144,790 shsMarket Capitalization$2.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Soligenix alerts: Email Address Ad Digital Mavericks Media1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.Click here to check it out. About Soligenix Stock (NASDAQ:SNGX)Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.Read More SNGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNGX Stock News HeadlinesJune 25, 2024 | prnewswire.comSoligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell LymphomaJune 14, 2024 | prnewswire.comA Comparison of Vaccine Technologies to be Presented at the ASM Microbe ConferenceJuly 5, 2024 | Golden Crest (Ad)DOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.May 31, 2024 | prnewswire.comSoligenix Announces Reverse Stock SplitMay 29, 2024 | prnewswire.comSoligenix Encourages Stockholders to Vote their Shares at the Annual MeetingMay 24, 2024 | prnewswire.comSoligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual MeetingMay 23, 2024 | prnewswire.comSoligenix Encourages Stockholders to Vote "FOR" Reverse Stock SplitMay 22, 2024 | finance.yahoo.comSoligenix, Inc. (SNGX)July 5, 2024 | Golden Crest (Ad)DOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.May 21, 2024 | finance.yahoo.comPRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the HorizonMay 21, 2024 | prnewswire.comSuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX ConferenceMay 20, 2024 | prnewswire.comSoligenix Encourages Stockholders to Vote Prior to Annual MeetingMay 16, 2024 | prnewswire.comPositive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical PracticeMay 14, 2024 | finance.yahoo.comSNGX: Second Confirmatory Phase 3 Trial of HyBryte™ in CTCL to Initiate Before End of 2024…May 13, 2024 | msn.comSNGX Stock Earnings: Soligenix Beats EPS, Misses Revenue for Q1 2024May 13, 2024 | finance.yahoo.comSoligenix First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 10, 2024 | prnewswire.comSoligenix Announces Recent Accomplishments And First Quarter 2024 Financial ResultsMay 6, 2024 | prnewswire.comSoligenix to Present at Upcoming ConferencesApril 25, 2024 | prnewswire.comSoligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaApril 18, 2024 | prnewswire.comSoligenix Announces Pricing of $4.75 Million Public OfferingApril 17, 2024 | investing.comSoligenix gains orphan drug status for MarVax vaccineApril 17, 2024 | finance.yahoo.comSage Therapeutics' Parkinson's drug fails in mid-stage studyApril 17, 2024 | finance.yahoo.comNanoscope Therapeutics to Present at the World Orphan Drug Congress 2024April 16, 2024 | benzinga.comSNGX: Agreement with EMA on Second Confirmatory Trial for HyBryte™April 16, 2024 | finanznachrichten.deSOLIGENIX, INC.: FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus InfectionApril 15, 2024 | finance.yahoo.comWhy Is Penny Stock Soligenix Trading Higher On Monday?April 15, 2024 | proactiveinvestors.comSoligenix surges as MarVax vaccine secures Orphan Drug Designation from FDASee More Headlines Receive SNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/05/2024Next Earnings (Estimated)8/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SNGX CUSIPN/A CIK812796 Webwww.soligenix.com Phone(609) 538-8200Fax609-452-6467Employees13Year Founded1987Profitability EPS (Most Recent Fiscal Year)($11.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,140,000.00 Net Margins-1,025.66% Pretax Margin-1,116.86% Return on Equity-198.36% Return on Assets-61.43% Debt Debt-to-Equity RatioN/A Current Ratio1.08 Quick Ratio1.08 Sales & Book Value Annual Sales$840,000.00 Price / Sales2.66 Cash FlowN/A Price / Cash FlowN/A Book Value$3.83 per share Price / Book0.59Miscellaneous Outstanding Shares990,000Free Float974,000Market Cap$2.24 million OptionableNot Optionable Beta1.88 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Christopher J. Schaber Ph.D. (Age 58)Chairman of the Board of Directors, CEO & President Comp: $625kMr. Jonathan L. Guarino CPA (Age 51)CGMA, Senior VP, CFO & Corporate Secretary Comp: $309.4kDr. Oreola Donini Ph.D. (Age 52)Senior VP & Chief Scientific Officer Comp: $342.31kDr. Richard C. Straube M.D. (Age 72)MSc., Senior VP & Chief Medical Officer Comp: $212.2kKey CompetitorsAridis PharmaceuticalsNASDAQ:ARDSMIRA PharmaceuticalsNASDAQ:MIRAAyala PharmaceuticalsNASDAQ:ADXSGraybug VisionNASDAQ:GRAYCan-Fite BioPharmaNYSE:CANFView All Competitors SNGX Stock Analysis - Frequently Asked Questions How have SNGX shares performed in 2024? Soligenix's stock was trading at $12.1152 at the beginning of the year. Since then, SNGX stock has decreased by 81.3% and is now trading at $2.26. View the best growth stocks for 2024 here. Are investors shorting Soligenix? Soligenix saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 39,900 shares, an increase of 183.0% from the May 31st total of 14,100 shares. Based on an average trading volume of 198,600 shares, the days-to-cover ratio is presently 0.2 days. Approximately 4.1% of the shares of the stock are short sold. View Soligenix's Short Interest. When is Soligenix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 19th 2024. View our SNGX earnings forecast. How were Soligenix's earnings last quarter? Soligenix, Inc. (NASDAQ:SNGX) released its quarterly earnings results on Friday, May, 10th. The biopharmaceutical company reported ($2.88) earnings per share for the quarter, beating analysts' consensus estimates of ($3.20) by $0.32. The biopharmaceutical company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative net margin of 1,025.66% and a negative trailing twelve-month return on equity of 198.36%. When did Soligenix's stock split? Shares of Soligenix reverse split before market open on Thursday, June 6th 2024. The 1-16 reverse split was announced on Thursday, June 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Soligenix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM). How do I buy shares of Soligenix? Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SNGX) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersUrgent Alert: Is the U.S. Implementing a Digital Dollar?Our exclusive guide, "Exploring the Future of the U.S. Dollar in a Digital World," is your essential resource ...Gold Gate Capital | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredDOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming...Golden Crest | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
